Description

You're referring to a combination medication that contains:

Metformin Hydrochloride (Extended Release - ER)

Glimepiride

Pioglitazone

These three are oral antidiabetic agents, commonly used together in the treatment of Type 2 Diabetes Mellitus (T2DM).

Breakdown of the Ingredients: 1. Metformin Hydrochloride (ER)
Class: Biguanide

Action:

Decreases hepatic glucose production

Increases insulin sensitivity

Improves peripheral glucose uptake

Extended-release (ER) formulation helps reduce gastrointestinal side effects and allows once-daily dosing.

2. Glimepiride
Class: Sulfonylurea

Action:

Stimulates the pancreas to release more insulin

Works best when some pancreatic function is preserved

3. Pioglitazone
Class: Thiazolidinedione (TZD)

Action:

Improves insulin sensitivity in muscle and adipose tissue

Reduces insulin resistance

Therapeutic Use:
This combination is typically prescribed when diet and exercise alone and/or monotherapy with a single oral agent does not provide adequate blood sugar control. It offers a multifaceted approach to manage blood glucose levels.

Common Brand Names
(In some countries/formulations, this combo is available under names like):

Trimetazidine (note: confirm with local listings)

Tripill MGP (generic)

But combinations and brand names may vary by country.

Important Considerations: Side Effects:
Metformin: GI upset, lactic acidosis (rare)

Glimepiride: Hypoglycemia, weight gain

Pioglitazone: Weight gain, fluid retention, risk of heart failure, possible bladder cancer risk (long-term)

Contraindications:
Renal impairment (especially for metformin)

Heart failure (pioglitazone)

Liver disease

Hypersensitivity to sulfonylureas (glimepiride)

Monitoring:
HbA1c levels every 3 6 months

Kidney and liver function tests

Signs of hypoglycemia or fluid retention